Aditxt (NASDAQ:ADTX – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.
Analyst Recommendations
This is a summary of recent ratings for Aditxt and Harrow, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Harrow | 2 | 1 | 8 | 0 | 2.55 |
Harrow has a consensus target price of $69.43, suggesting a potential upside of 77.79%. Given Harrow’s stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than Aditxt.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.41 | -$41.71 million | ($100,788.35) | -0.00 |
| Harrow | $275.59 million | 5.31 | -$5.14 million | ($1.00) | -39.05 |
Harrow has higher revenue and earnings than Aditxt. Harrow is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Aditxt has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.
Profitability
This table compares Aditxt and Harrow’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Harrow | -13.51% | -38.00% | -3.37% |
Summary
Harrow beats Aditxt on 12 of the 14 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
